Healthcare of Ontario Pension Plan Trust Fund Invests $1.99 Million in AtriCure, Inc. (NASDAQ:ATRC)

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 71,000 shares of the medical device company's stock, valued at approximately $1,991,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.15% of AtriCure at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Canada Pension Plan Investment Board boosted its stake in shares of AtriCure by 187.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 110,669 shares of the medical device company's stock worth $2,520,000 after acquiring an additional 72,200 shares in the last quarter. Renaissance Technologies LLC boosted its position in AtriCure by 12.8% during the second quarter. Renaissance Technologies LLC now owns 171,700 shares of the medical device company's stock worth $3,910,000 after purchasing an additional 19,500 shares in the last quarter. SG Americas Securities LLC acquired a new stake in AtriCure in the third quarter valued at $488,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of AtriCure by 31.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company's stock valued at $14,038,000 after buying an additional 119,929 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of AtriCure by 151.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company's stock worth $6,425,000 after buying an additional 138,046 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ATRC shares. Needham & Company LLC increased their price objective on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Oppenheimer upped their target price on AtriCure from $32.00 to $36.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. UBS Group raised their price target on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Canaccord Genuity Group increased their price objective on AtriCure from $49.00 to $53.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their price objective on AtriCure from $30.00 to $40.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $41.00.

AtriCure Trading Up 2.5 %

ATRC traded up $0.90 during midday trading on Monday, hitting $37.06. The company's stock had a trading volume of 476,299 shares, compared to its average volume of 712,304. The firm has a 50-day moving average price of $31.71 and a two-hundred day moving average price of $26.42. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $39.04. The firm has a market cap of $1.81 billion, a P/E ratio of -43.57 and a beta of 1.41.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to analysts' expectations of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The business's quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.20) EPS. On average, research analysts anticipate that AtriCure, Inc. will post -0.72 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.